Do you want to read an article? Please log in or register.
Serum mesothelin as a response biomarker in pleural mesothelioma
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
Lung Cancer
Ono S, Taniguchi H, Kuroda K, Hashimoto T, Okada A, Goto Y, Kitai H, Nakamura Y, Ogusu S, Hase T, Ota T, Ebi N, Furugen M, Harada T, Kinoshita Y, Mizoguchi T, Nakatomi K, Soejima Y, Yamada T, Takemoto S, Mukae H
doi: 10.1016/j.lungcan.2025.108709
Lung, Respiratory and Thoracic Cancer
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Lung Cancer
Shah R, Buchmeier EL, Kopp HG, Christoph DC, Griesinger F, Reck M, Hoffknecht P, Kuon J, Frost N, Grohé C, Faehling M, Luan J, Roeper J, Chesi P, Blasi M, Kimmich M, Olchers T, Bischoff H, Klotz LV, Chung I, Christopoulos P, Thomas M
doi: 10.1016/j.lungcan.2025.108702
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G
doi: 10.1200/JCO-25-01328
Breast Cancer
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Ann Oncol
Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F
doi: 10.1016/j.annonc.2025.11.007
Further Publications
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
Ann Oncol
Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G
doi: 10.1016/j.annonc.2025.03.019
Skin Cancer
Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Lancet Oncol
Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D
doi: 10.1016/S1470-2045(25)00139-1
Multiple Myeloma (MM)
Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM
EHA 2025
Multiple Myeloma (MM)
RedirecTT-1: Deep and durable responses with talquetamab plus teclistamab in RRMM patients with extramedullary disease
Further Publications
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)
Ann Oncol
Aldea M, Salto-Tellez M, Marra A, Umeton R, Stenzinger A, Koopman M, Prelaj A, Kehl KL, Gilbert S, Leßmann ME, Lipkova J, Provenzano L, Meric-Bernstam F, Halabi S, Wu J, Pellat A, Suijkerbuijk KPM, Besse B, Ryll B, Marchió C, Crispin-Ortuzar M, Fehrmann R, Vibert J, Ferber D, Pauli C, Valachis A, Corso F, Brinker TJ, Mateo J, Harbeck N, Winkler EC, Lopez-Rios F, Perez-Lopez R, Pentheroudakis G, Delaloge S, Benedikt Westphalen C, Kather JN
doi: 10.1016/j.annonc.2025.11.009